The magnitude of OS benefit with upfront HDT is cytogenetics-dependent. Patients with high-risk cytogenetics should preferably receive upfront rather...
This is likely attributable to underlying disease biology and prevention of end-organ damage by early treatment initiation, as benefit was independent...